Today the Charlotte Lozier Institute releases its seventh Stem Cell Research Facts video which returns to the life of lupus survivor Jackie Stollfus and how her adult stem cell transplant opened up new vistas many previously thought impossible.
Paul Wagle, M.A., is the Director of Life Science Development for the lead economic agency in the state of Kansas. Mr. Wagle was diagnosed with leukemia at the age of 10, and after a four-year battle including an adult stem cell transplant, he has been cured for over 10 years.
Today the Charlotte Lozier Institute releases its sixth in its series of Stem Cell Research Facts videos. This story features the work of Dr. Joseph McGuirk, an adult stem cell expert at the University of Kansas Hospital, and tells the story of Chance Runnion’s recovery from leukemia after an adult stem cell transplant.
In 2014, Minnesota became the most recent of a handful of states that provide state funding for all types of stem cell research, including human embryonic stem cell research. The law provides for 10 years of funding with $4.5 million approved for the first year and $4.35 million each year thereafter.
The Maryland Stem Cell Research Fund (MSCRF) has awarded two rounds of grants since the Charlotte Lozier Institute last analyzed the Fund’s pattern of grant making for stem cell research, in the fall of 2013. That study found that since MSCRF first began awarding grants in 2007, its pattern of giving shifted over the years from strongly favoring projects focusing on ethically contentious human embryonic stem cell research (hESCR) to projects focusing on ethically non-contentious adult stem cells and other non-embryonic stem cell research.
Today the Charlotte Lozier Institute releases its fourth Stem Cell Research Facts video; this story features Cindy Schroeder’s recovery from multiple myeloma after an adult stem cell transplant.
A recent press release from the National Institutes of Health calls attention to a study, published in Stem Cell Reports, that researchers have “developed a clinical-grade stem cell line, which has the potential to accelerate the advance of new medical applications and cell-based therapies for millions of people suffering from such ailments as Alzheimer’s disease, Parkinson’s disease, spinal cord injury, diabetes, and muscular dystrophy.” The development of these clinical grade stem cells, the release notes, “removes a significant barrier in the development of cell-based therapies.” But is NIH’s promotion of “stem cells” anything new?